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Objective: To investigate the effect of dehydroepiandrosterone (DHEA) supplementation on women with
poor ovarian response (POR).
Materials and methods: Women with POR treated with ﬂexible daily gonadotropin-releasing hormone
antagonist in vitro fertilization (IVF) cycles at The Reproductive Center in Kaohsiung Veterans General
Hospital between January 2013 and October 2013, were enrolled for this prospective study. When pa-
tients failed to become pregnant during the ﬁrst IVF cycle, they were treated with DHEA supplemen-
tation (30 mg, 3 times a day, orally) for 3 months (mean 12.2 weeks) before the next IVF cycle.
Parameters of biochemical, ultrasound and treatment outcomes were compared before and after DHEA
supplementation.
Results: Ten patients with a mean age of 36.6 ± 4.2 years were identiﬁed. After DHEA treatment, there
was a signiﬁcant increase in antral follicle count, from 2.8 ± 1.0 to 4.1 ± 1.2 (p < 0.05), and anti-Müllerian
hormone, from 0.4 ± 0.2 ng/mL to 0.84 ± 0.2 ng/mL (p < 0.001). A signiﬁcant decrease of Day 3 follicle-
stimulating hormone and estradiol, from 14.4 ± 1.7 mIU/mL to 10.1 ± 0.7 mIU/mL and from 51.2 ± 6.3 pg/
mL to 35.2 ± 4.2 pg/mL, respectively (both p < 0.001), was noted. Increased numbers of retrieved oocytes
(from 2.4 ± 1.1 to 4.2 ± 1.2; p < 0.01), fertilized oocytes (from 1.7 ± 0.5 to 3.8 ± 1.1; p < 0.001), Day 3
embryos (from 1.7 ± 0.5 to 3.7 ± 1.1; p < 0.001) and transferred embryos (from 1.7 ± 0.8 to 2.8 ± 0.8;
p < 0.01) were also seen in these women with POR after DHEA treatment. Three women became
pregnant after DHEA treatment.
Conclusion: The potential beneﬁts of DHEA supplementation in women with POR were suggested by the
biochemical parameters and IVF outcomes.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.epartment of Obstetrics and
epartment of Obstetrics and
of Medicine, 201, Section 2,
cience, National Sun Yat-Sen
heng), phwang@vghtpe.gov.
bstetrics & Gynecology. PublishedIntroduction
Ovarian reserve, a residual follicular pool in women, is a crucial
predictor for assisted reproductive technology outcomes. The Eu-
ropean Society of Human Reproduction and Embryology
Campus Workshop in Bologna standardized the deﬁnition of
abnormal ovarian reserve (diminished ovarian reserve, DOR) andby Elsevier Taiwan LLC. All rights reserved.
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three features that must be present: (1) advanced maternal age or
any other risk factor for POR; (2) a previous POR; and (3) an
abnormal ovarian reserve test (ORT) [1]. In addition, two episodes
of POR after maximal stimulation would be sufﬁcient to deﬁne a
patient as a poor responder in the absence of advanced maternal
age or abnormal ORT [1]. Women with DOR or POR, estimated to
occur in 5e18% of in vitro fertilization (IVF) cycles, present a sig-
niﬁcant challenge in assisted reproductive technology, partly
because these women have poor IVF outcomes with extremely low
pregnancy rates (2e4%), in spite of the use of various stimulation
protocols and downregulation strategies [2,3].
Dehydroepiandrosterone (DHEA), a precursor of estradiol (E2)
and testosterone (T), originates from the adrenal zona reticularis
and from ovarian theca cells [4e6]. Both estrogen and androgen are
considered to be required for normal follicular development and
fertility [6e9]. In recent years, since Casson et al ﬁrst reported the
beneﬁcial effects of DHEA supplementation on ovarian response
among patients with DOR [10], androgens and their precursors
have been proposed as an adjunctive treatment in poor responders
[10e16]. However, the effect of DHEA supplementation on POR is
still inconsistent. The reasons might be secondary to the European
Society of Human Reproduction and Embryology consensus,
which allows for clinical heterogeneity within the newly deﬁned
population, since clinical heterogeneity, when present, has impli-
cations for the design of research studies [17]. The aim of this study
was to investigate the effect of DHEA supplementation on ovarian
reserve in patients with DOR.
Material and methods
Patients and design
This study received Institutional Review Board approval from
the Committee for Human Research at Kaohsiung Veterans General
Hospital, with the identiﬁer VGHKS13-CT11-17, and was registered
at ClinicalTrials.gov with the identiﬁer NCT02150330. All women
were fully counseled, and their written consent was obtained. All
patients treated with IVF cycles at The Reproductive Center in
Kaohsiung Veterans General Hospital between January 2013 and
October 2013 were enrolled for this prospective study. However,
patients with a history of the following clinical situations: ovarian
cystectomy, oophorectomy, exposure to cytotoxic or pelvic irradi-
ation for malignancy, or those taking herbal drugs or other hor-
monal agents, were excluded. Patients who met the Bologna poor
responder criteria [1] were enrolled. To make the population more
homogeneous, the following criteria were added: those patients
who had serum follicle-stimulating hormone (FSH) > 15 nIU/L, or
serum anti-Müllerian hormone (AMH) < 1 ng/mL, and abnormally
low antral follicle counts (AFC) < 4 on Day 2 of their menstrual
cycle, and of importance, had an unsuccessful ﬂexible daily
gonadotropin releasing hormone (GnRH) antagonist IVF cycle fol-
lowed by DHEA supplementation (CPH; Formulation Technology,
Oakdale, CA, USA). Women who fulﬁlled the above criteria were
included in the study for analysis.
Treatment protocols
The patients who arrived at their IVF cycle were treated ac-
cording to a ﬂexible daily GnRH antagonist protocol. Ovarian
stimulation was initiated on Day 2 of the menstrual cycle with
300 IU daily recombinant FSH (rFSH, Gonal-F; Merck KGaA,
Darmstadt, Germany), which was continued for the ﬁrst 5 days of
stimulation; then, daily dosing was adjusted according to follicular
development and serum estradiol. GnRH antagonist (Cetrotide0.25 mg; Merck KGaA) was administered starting from when the
leading follicle reached a diameter of 12~14 mm. Serial estradiol
levels were detected and follicular growth was monitored by
transvaginal ultrasound (SSA-550A; Toshiba, Sakai, Osaka, Japan).
Recombinant human chorionic gonadotropin (Ovidrel; Merck
KGaA) was administered until at least one dominant follicle
reached  17 mm in diameter, and was followed by transvaginal
oocyte retrieval 34e36 hours later. Fertilization was determined by
the presence of two pronuclei on the ﬁrst day after insemination.
Embryo transfer was done on Days 3e5, depending on the embryo
status.
Luteal phase support was given routinely as daily progesterone
(Crinone 8% gel; Merck KGaA; Utogestin; NetDoctor, London, UK)
for 14 days when a pregnancy test was performed [18,19]. In
addition, all patients received three doses of 250 mg Ovidrel on the
3rd, 6th, and 9th days after oocyte retrieval. For patients with a
positive pregnancy test, progesterone was continued for an addi-
tional 6 weeks. Clinical pregnancy was conﬁrmed if a fetal heart-
beat was observed in an intrauterine gestational sac by transvaginal
ultrasound.
All womenwhowere treatedwith the above protocol but had an
unsuccessful IVF cycle received DHEA supplementation (30 mg, 3
times a day, orally) for 3 months (mean 12.2 weeks) before the next
IVF cycle.
Total doses of rFSH, days of stimulation, oocytes retrieved,
fertilized oocytes, Day 3 embryos, and transferred embryos were
determined before and after DHEA supplementation.
Statistical analysis
Data analysis was performed using the Statistical Package for
the Social Sciences Version 22.0 (SPSS Inc., Chicago, IL, USA). Data
are presented as the mean ± standard deviation. Statistical com-
parisons were performed using a two-tailed Student t test. A p-
value of <0.05 was considered to be statistically signiﬁcant.
Results
The mean age and body mass index of the patients were
36.6 ± 4.2 years and 21.4 ± 2.5 kg/m2, respectively. Mean Day 3 FSH
and estradiol concentrations were signiﬁcantly lower after DHEA
supplementation than before (14.4 ± 1.7 mIU/mL vs.10.1 ± 0.7 mIU/
mL; p < 0.001, and 51.2 ± 6.3 pg/mL vs. 35.2 ± 4.2 pg/mL; p < 0.001,
respectively). The other ovarian reserve markers, such as AMH
concentrations, increased from 0.4 ± 0.2 ng/mL to 0.8 ± 0.2 ng/mL
after DHEA supplementation, which amounted to a 2-fold increase
(p < 0.001). A similar changewas found in the AFC, which increased
signiﬁcantly from 2.8 ± 1.0 to 4.1 ± 1.2, amounting to a 1.5-fold
increase (p < 0.05; Fig. 1). Total doses of rFSH (3480 ± 1193 IU vs.
3060 ± 878 IU; p ¼ 0.381) and days of stimulation (11.9 ± 3.4 days
vs. 10.8 ± 0.8 days; p ¼ 0.338) before and after DHEA supplemen-
tation were not statistically signiﬁcantly different. Consistent with
the signiﬁcant improvement in ovarian reserve markers and
ovarian response in these womenwith DOR undergoing IVF cycles,
the number of oocytes retrieved (from 2.4 ± 1.1 to 4.2 ± 1.2;
p < 0.01), number of fertilized oocytes (from 1.7 ± 0.5 to 3.8 ± 1.1;
p < 0.001) and number of Day 3 embryos (from 1.7 ± 0.5 to
3.7 ± 1.1; p < 0.001) also increased after DHEA treatment,
compared with those before. The number of transferred embryos
increased signiﬁcantly (1.7 ± 0.8 vs. 2.8 ± 0.8; p < 0.01) after DHEA
supplementation. Although the ﬁnal outcomedthe clinical preg-
nancy rateddid not reach statistical signiﬁcance after DHEA
treatment (p ¼ 0.065), there were 3 ongoing clinical pregnancies
after DHEA treatment, compared with no pregnancy before
(Table 1).
Fig. 1. Ovarian reserve markers [follicle-stimulating hormone (FSH), abnormally low antral follicle counts (AFC), and anti-Müllerian hormone (AMH)] before and after dehydro-
epiandrosterone (DHEA) supplementation (mean and standard error). ＃p < 0.05.
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In terms of ovarian reserve markers, Casson et al ﬁrst disclosed
an increase in peak estradiol concentrations, from 266.3 ± 69.4 pg/
mL to 939.8 ± 418.9 pg/mL (p ¼ 0.02), and in the estradiol/ampoule
ratio (by a mean of 2.94 ± 0.50 fold; p ¼ 0.012), respectively, after
DHEA supplementation [11]. Improvement in peak estradiol con-
centrations following DHEA was also found in subsequent studies
[14,15]. Gleicher et al ﬁrst reported that DHEA supplementation
could signiﬁcantly increase AMH concentrations (from
0.22 ± 0.22 ng/mL to 0.35 ± 0.03 ng/mL; p ¼ 0.002) over time,
especially in younger women (under 38 years) [10]. Yilmaz et al
found that ovarian reservemarkers, including AMH (0.32 ± 0.29 ng/
mL vs. 0.75 ± 0.70 ng/mL; p ¼ 0.001), AFC (4.12 ± 0.70 vs.
4.37 ± 0.94; p ¼ 0.002), inhibin B (21.96 ± 21.79 pg/mL vs.
46.12 ± 28.31 pg/mL; p ¼ 0.001), FSH (13.73 ± 8.27 mIU/mL vs.
10.36 ± 6.18 mIU/mL; p ¼ 0.001) and E2 (51.78 ± 12.48 pg/mL vs.
35.25 ± 13.18 pg/mL; p ¼ 0.001) signiﬁcantly improved after DHEA
therapy [12]. However, Hyman et al reported a signiﬁcant increase
in AFC (5.3 ± 2.8 vs. 3.6 ± 1.5; p < 0.001), but no signiﬁcant changes
in the baseline biochemical parameters, including AMH, inhibin B,
and FSH, following DHEA supplementation, suggesting that the
effect of DHEA on the improvement of ovarian reserve might be
mediated by rescuing small antral follicles from atresia (increasedTable 1
Clinical and laboratory parameters and treatment outcomes of 10 womenwith poor
ovarian response (poor responders) before and after DHEA supplementation.
Baseline n ¼ 10,
Mean ± SD
After DHEA
treatment n ¼ 10,
Mean ± SD
p
Age (y) 36.6 ± 4.2 36.6 ± 4.2 d
BMI (kg/m2) 21.4 ± 2.5 21.4 ± 2.5 d
FSH (mIU/mL) 14.4 ± 1.7 10.1 ± 0.7 <0.001
Estradiol (pg/mL) 51.2 ± 6.3 35.2 ± 4.2 <0.001
Antral follicle count (n) 2.8 ± 1 4.1 ± 1.2 <0.05
AMH (ng/mL) 0.4 ± 0.2 0.84 ± 0.2 <0.001
Total doses of rFSH (IU) 3480 ± 1193.3 3060 ± 878.1 0.381
Days of stimulation (d) 11.9 ± 3.4 10.8 ± 0.8 0.338
Oocytes retrieved (n) 2.4 ± 1.1 4.2 ± 1.2 <0.01
Fertilized oocytes (n) 1.7 ± 0.5 3.8 ± 1.1 <0.001
Day 3 embryos (n) 1.7 ± 0.5 3.7 ± 1.1 <0.001
Transferred embryos (n) 1.7 ± 0.8 2.8 ± 0.8 <0.01
AMH ¼ anti-Müllerian hormone; BMI ¼ body mass index;
DHEA ¼ dehydroepiandrosterone; FSH ¼ follicle-stimulating hormone;
rFSH ¼ recombinant follicle-stimulating hormone; SD ¼ standard deviation.AFC), but not by recruitment of preantral or very small antral fol-
licles (no change in AMH and inhibin B) [14]. However, Singh et al
showed that DHEA treatment resulted in a signiﬁcant increase in
serum AMH (p < 0.05) and a signiﬁcant decrease in Day 2 FSH
(p < 0.05) in all age groups, but there was no statistically signiﬁcant
difference in AFC [15]. A small pilot trial fromHong Kong concluded
that there was no statistically signiﬁcant improvement in ovarian
response markers, ovarian response to standard dose gonadotropin
stimulation, or IVF outcomes in poor responders receiving pre-
treatment DHEA [16]. Our ﬁndings seem to be similar to those of
Yilmaz et al [12], with a signiﬁcant improvement in both ovarian
reserve markers (AMH, FSH, and estradiol) and ovarian response
(AFC) after DHEA therapy (Fig. 1). A possible explanation for these
conﬂicted data is clinical heterogeneity [13,17], such as small
sample sizes, different patient ages, different included populations
and different treatment durations. This problem occurs even in
randomized controlled trials (RCTs), since potential result bias may
be introduced if women from each subpopulation are not evenly
allocated between intervention groups [12]. In the case of small or
moderate-size RCTs, a single-sequence randomization method may
not ensure balanced allocation between groups [20,21]. A large
prospective RCT would be needed to clarify this.
In term of oocytes and embryo yields and quality, Barad and
Gleicher [22] ﬁrst attempted to analyze the outcome of IVF cycles in
25 patients who underwent cycles both before and after DHEA
supplementation. They found a signiﬁcant increase in oocytes
retrieved (4.4 ± 0.5 vs. 3.4 ± 0.5; p < 0.05), fertilized oocytes
(3.0 ± 0.5 vs. 1.4 ± 0.3; p < 0.001), normal Day 3 embryos (2.7 ± 0.4
vs. 1.2 ± 0.2; p ¼ 0.001), Day 3 embryo grade (3.4 ± 0.1 vs. 2.9 ± 0.1;
p¼ 0.02) and transferred embryos (2.4 ± 0.3 vs.1.4 ± 0.2; p¼ 0.005)
after DHEA treatment [22]. In a subsequent cohort of 19 DOR pa-
tients, an increased number of follicles >17 mm (3.0 ± 0.7 vs.
1.9 ± 1.3; p < 0.05), metaphase II oocytes (4.0 ± 1.8 vs. 2.1 ± 1.8;
p < 0.05), and top-quality Day 2 (2.2 ± 0.8 vs. 1.3 ± 1.1; p < 0.05) and
Day 3 embryos (1.9 ± 0.8 vs. 0.7 ± 0.6; p < 0.05) were achieved in
DHEA-supplemented cycles [23]. In a recent study, Hyman et al
showed the beneﬁcial effect of DHEA treatment on poor re-
sponders, including an increased number of follicles >15 mm (from
2.7 ± 1.6 to 4.5 ± 3.1; p¼ 0.004), number of oocytes retrieved (from
1.9 ± 1.2 to 4.4 ± 3.2; p < 0.001), and number of metaphase II oo-
cytes (from 1.6 ± 1.1 to 3.2 ± 2.2; p < 0.001) [14]. There was also an
increased number of transferable embryos (p < 0.001) and an in-
crease in the percentage of high-quality embryos in younger pa-
tients (p ¼ 0.01) [14]. In addition, Wiser and colleagues conducted
Table 2
Articles review of effects of DHEA supplementation in women with diminished ovarian reserve and/or poor ovarian response.
Author (y) No. of SP
or (SP/C)
Mean age (y) *Inclusive criteria DHEA
(dose and duration)
Outcome Note※
Zangmo (2014) [31]. 50 34.1 Age <42 y, with <5 oocytes
retrieved in previous IVF cycles,
Day-2 FSH 10e20 mIU/mL
75 mg daily, 4 mo Beneﬁts in retrieval oocytes, MII
oocytes, fertilized oocytes, grade I
embryos and transferred embryos
Pro
Poli (2014) [32]. 29 d With evidence of DOR and poor-
responders to a previous treatment
75 mg daily, 8 wk Beneﬁts in retrieval oocytes and
oocyte quality
Reduction of cancelled cycles
Pro
Yeung (2014) [16]. (16/16) 36.0 Age <40 y, subfertility >1 year, and
expected poor ovarian response
deﬁned as AFC <5
25 mg tid, 12 wk No beneﬁts in ovarian response
markers, ovarian response, or IVF
outcomes
Pro
Kara (2014) [33]. (104/104) 31.0 AMH <1 ng/mL or FSH >15 IU/l and
AFC <4 on Day 2 of the menstrual
cycle
75 mg daily, 12 wk No beneﬁts in IVF outcomes Pro
Yeung (2013) [30]. (10/12) 35.9 Age <40 y, secondary amenorrhea,
FSH >30 IU/l on 2 occasions of at
least 6 wk, normal karyotype of
46XX, negative FMR1 gene
mutation.
25 mg tid, 16 wk Beneﬁts in higher AFC and ovarian
volume, but no beneﬁts in serum
AMH and FSH levels
Pro
Yilmaz (2013) [12]. 41 33.8 AFC <5 or AMH <1.1 ng/mL and a
previous poor ovarian response
25 mg tid, 6 wk Improvement in ovarian reserve
markers
(FSH, E2, AFC, AMH and inhibin B)
Pro
Hyman (2013) [14]. 32 37.6 Previous oocyte retrieval no more
than 4 oocytes
75 mg daily, 3 mo Improvement in ovarian reserve
markers
(AFC, not FSH, AMH and inhibin B)
Improvements in peak estradiol,
follicles >15 mm, oocytes, MII




Singh (2013) [15]. 30 34.3 Poor ovarian response in the
previous IVF cycle(s)
25 mg tid, 4 mo Improvement in ovarian reserve
markers (FSH, AMH, not AFC)
Pro
Fusi (2013) [26]. (38/24) 40.6 AFC <4, FSH >10 IU/mL, AMH
<1 ng/mL
25 mg tid, 12 wk Improvement in spontaneous
pregnancies
Retro
Gleicher (2010) [11]. 120 39 Elevated age-speciﬁc FSH
concentrations* or AMH <0.8 ng/mL
25 mg tid, 30e120 d Improvement in ovarian reserve
marker (AMH)
Retro
Gleicher (2010) [29]. (22/44) 37.9 Abnormally elevated age-speciﬁc
baseline FSH or abnormally low
age-speciﬁc AMH levels
25 mg tid, 4e12 wk Reduction in aneuploid embryos Retro
Wiser (2010) [24]. 17 36.9 Prior poor response to ovarian
stimulation in IVF
75 mg daily, 6 wk Improvements in embryo quality
and live birth rate
Pro, RCT
S€onmezer (2009) [23]. 19 32.9 Cycle cancellation or <4 retrieved
oocytes in prior IVF cycle(s)
25 mg tid, 3 mo Improvements in Day 3 E2,
follicles > 17mm, oocytes retrieved,




Gleicher (2009) [27]. 73 Stratiﬁed
by age,
Age >40 y or elevated age-speciﬁc
baseline FSH
25 mg tid, 2 mo Reduction in miscarriage rate Retro
Barad (2007) [25]. (89/101) 41.6 Premature ovarian aging:
FSH 7.4 mIU/mL (30e34 y)
FSH 8.6 mIU/mL (35 y)
Diminished ovarian reserve:
FSH 12 mIU/mL and/or E2 level
75 pg/mL
75 mg daily, 4 mo Improvement in cumulative
pregnancy rate
Retro
Barad (2006) [22]. 25 39.9 FSH levels >10 mIU/mL or E2 levels
>75 pg/mL
25 mg tid, 4 mo
(mean 17.6 wk)
Improvements in oocytes retrieved,
fertilized oocytes, normal Day 3




Casson(2000) [10]. 5 35~40 Previous poor ovarian response
(peak E2 <500 pg/mL, mature
follicles 2)
80 mg daily, 2 mo Improvements in peak E2 and
responsiveness to gonadotropins
Pro
Current study 10 36.6 Poor responder, including FSH
>15 nIU/l, AMH <1 ng/mL, as AFC
<4 on Day 2 of menstrual cycle,
prior failure of IVF cycle
30 mg tid, 3 mo
(mean 12.2 wk)
Improved Improvement in ovarian
reserve markers (FSH, AMH, E2,
AFC)
Improvements in oocytes retrieved,
fertilized oocytes, Day 3 embryos
and transferred embryos
AFC ¼ antral follicle count; AMH ¼ anti-Müllerian hormone; C ¼ controls; E2 ¼ estradiol; FSH ¼ follicle-stimulating hormone; IVF ¼ in vitro fertilization; MII ¼metaphase II;
*Pro ¼ prospective; Retro ¼ retrospective; SP ¼ study participants; tid ¼ three times per day.
*Age-speciﬁc FSH cut offs: < 7.0 mIU/mL (<33 mIU/mL); <7.9 mIU/mL (33e37 mIU/mL); <8.4 mIU/mL (38e40 mIU/mL); <8.5 mIU/mL (>41 mIU/mL).
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data and outcomes among poor-responder patients, and found an
improved embryo score during treatment, between the ﬁrst and
second cycles (from 2.7 ± 0.5 to 3.5 ± 0.4; p¼ 0.04) [24]. Consistent
with the above studies, the results of our study showed a signiﬁ-
cantly increased number of oocytes retrieved, fertilized oocytes,
Day 3 embryos and transferred embryos in IVF cycles after DHEA
treatment.
In addition, pregnancy rates were supposed to rise after DHEA
treatment, because of improved ovarian reserve and possibly
improved oocytes/embryo yields and quality. In a case control
study of 89 DOR patients with DHEA supplementation and 101
controls, cumulative clinical pregnancy rates were signiﬁcantly
higher in the DHEA group (28.4% vs. 11.9%; p < 0.05) [25]. S€onmezer
et al reported that DHEA treatment resulted in signiﬁcantly higher
pregnancy rates (47.4% vs. 10.5%; p < 0.01) [23]. In another study of
patients waiting for IVF, both pregnancy rate and ongoing preg-
nancy rate were signiﬁcantly higher in the DHEA-treated group
than in the control group (21.1% vs. 4.1%; p < 0.05 and 13.2% vs. 0%;
p < 0.01, respectively), suggesting that DHEA alone could raise
fecundity and fertility treatment success in women with a poor
prognosis for pregnancy [26]. In our study, 3 women conceived
after DHEA supplementation; this increase in the pregnancy rate
did not reach statistical signiﬁcance, but we believe that might be
because of the small sample size (n ¼ 10).
In one study, the miscarriage rates after DHEA therapy were
signiﬁcantly lower in women at all ages, especially those above age
35 years (odds ratio 0.49; 95% conﬁdence interval 0.25e0.94;
p ¼ 0.04) [27]. Since approximately 80% of ﬁrst trimester arrested
pregnancies is the consequence of abnormal karyotypes, reduced
aneuploidy may lead to reduced miscarriage rates [28]. In a 1:2
matched caseecontrol study, 22 DOR patients supplemented with
DHEA and 44 control patients underwent preimplantation genetic
screening of embryos during IVF cycles. Those with DHEA supple-
mentation were found to have a signiﬁcant reduction in the num-
ber (2.8 ± 2.5 vs. 4.5 ± 3.1; p ¼ 0.029) and percentage (38.2 ± 24.4%
versus 61.0 ± 22.4%; p < 0.001) of aneuploid embryos [29]. With the
increased pregnancy rate and decreasedmiscarriage rate inwomen
with DOR after DHEA treatment, DHEA may also positively affect
live birth rates.Wiser et al reported that patients in the DHEA group
had a signiﬁcantly higher live birth rate than the controls (23.1% vs.
4.0%; p ¼ 0.05) [24]. A summary of recent publications addressing
the effects of DHEA supplementation on patients with DOR is
included (Table 2) [10e12,14e16,20e25,29e33].
DHEA ameliorated almost all parameters of biochemical, ultra-
sound, and treatment outcomes in DOR patients (Table 3). The
beneﬁcial effects of DHEA increased with length of supplementa-
tion [11,25].Table 3
Summary of effects of DHEA supplementation in women with diminished ovarian
reserve and/or poor ovarian response.
Effects of DHEA References
Primary effects
Improvement in ovarian reserve [11,12,14,15]
Improvement in ovarian response [10,14,15,31,32]
Improvement in oocytes and embryo yields [14,22,23,31,32]
Improvement in oocytes and embryo quality [14,22e24,32]
Reduction in aneuploid embryos [29]
Secondary effects
Improvement in pregnancy rates of IVF [23,25]
Improvement in spontaneous pregnancies [26]
Reduction in miscarriage rates [27]
Improvement in live birth rates of IVF [24]
Reduction in cancellation of IVF [14,22,23]
DHEA ¼ dehydroepiandrosterone; IVF ¼ in vitro fertilization.Despite the plentiful beneﬁts of DHEA treatment (Table 3), the
mechanism of the effects of DHEA on improving reproductive
outcomes in DOR patients remains speculative. DHEA serves as a
prohormone of the follicular ﬂuid testosterone during ovarian in-
duction with exogenous gonadotropins [34]. Androgen receptors
were detected in the ovarian stroma and granulosa cells of pri-
mordial follicles, and were more clearly seen in primary follicles
and more advanced-stage follicles [35]. Granulosa cell-speciﬁc
androgen receptors appear to promote preantral follicle develop-
ment and prevent follicular atresia [9]. Hence, androgen is essential
for normal folliculogenesis and fertility. By increasing androgen
levels in the granulosa cells, DHEA treatment may increase
expression of FSH receptors [36], induce a temporary polycystic-like
state [18], and result in enhanced response to ovarian stimulation.
In addition, DHEA supplementation may rescue follicles from
atresia, promote preantral follicle growth [9,37,38], suppress
apoptosis [35] and bring on improved ovarian reserve and oocyte
yields.
Supplementation with DHEA elevated insulin-like growth
factor-I (IGF-I)/IGF binding protein-3 (IGFBP-3) levels [39], perhaps
mediated via increasing androgen [40]. The IGF-I/IGFBP-3 ratiomay
be indicative of oocyte quality and maturity [41]. Furthermore, IGF-
1 had positive effects on embryo quality and development [42,43].
Therefore, DHEA therapy may lead to improvement in oocytes and
embryo quality. Taken together, DHEAmay return the aging ovaries
to a younger condition; possible mechanisms are shown in Fig. 2.
The limitations of our study include the small population size
and the non-randomized controlled study design, which were
common limitations in previous studies. Eligible patients with DOR
are quite few in IVF cycles. In addition, patients with DOR always
have a limited time to conceive and are unwilling to take part in a
randomized trial, in which they may be distributed to the placebo
group. As a consequence, most published data on DHEA are either
cohort or caseecontrol studies. Nevertheless, we look forward to
large, multicenter, RCTs to validate the potential effects of DHEA
treatment on DOR patients.
In conclusion, DHEA supplementation has primary and sec-
ondary beneﬁcial effects on patients with DOR and can be pre-
scribed to those patients before entry into oocyte donation.Fig. 2. The possible mechanism of effects following DHEA supplementation in patients
with diminished ovarian reserve. DHEA supplementation may involve in inducing FSH
receptors, leading to a PCO state, rescuing atresic follicles, promoting follicles devel-
opment, reducing apoptosis and increasing IGF-I/IGFBP-3 ratio via elevating androgen
level. DHEA ¼ dehydroepiandrosterone; FSH ¼ follicle-stimulating hormone; IGF-
1 ¼ insulin-like growth factor-I; IGFBP-3 ¼ insulin-like growth factor binding protein-
3; PCO ¼ polycystic ovary.
K.-H. Tsui et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 131e136136However, large, multicenter RCTs are needed to conﬁrm the results.
Several possible mechanisms of DHEA effects have been proposed,
and may be related to DHEA-enhanced levels of androgen. We also
need further in-depth research to explore howDHEAworks on DOR
patients.
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